SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

Other languages Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Hong Kong S.E.

Equities

2196

CNE100001M79

Delayed Hong Kong S.E. Other stock markets 22:42:52 2024-05-20 EDT			5-day change	1st Jan Change
13.08 ^HKD	-3.40%		-2.39%	-23.06%

05-15	Fosun Pharma Unit Fosun Health to Receive Capital Injection from Foshan Chanxi City Investment	MT
05-15	China Approves Clinical Trials For Breast Cancer Drugs	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fosun Pharma Unit Fosun Health to Receive Capital Injection from Foshan Chanxi City Investment	05-15
China Approves Clinical Trials For Breast Cancer Drugs	05-15
Fosun Pharma Unit Gets China Marketing Approval for Schizophrenia Tablets	05-09
Shanghai Fosun Pharmaceutical Unit Secures China Nod to Sell Schizophrenia Drug	05-09
US FDA Grants Clinical Trial Approval for Fosun Unit's Gastric Cancer Tablets	05-07
Fosun Pharma's Q1 Profit Slumps 38%	04-30
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29
Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator	04-24
China Accepts New Drug Applications for Fosun Pharma's Iron Overload Syndrome Drugs	04-08
Fosun Pharma's 2023 Attributable Profit Declines, Misses Estimates	03-26
Shanghai Fosun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	03-26
Shanghai Fosun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023	03-26
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26
Shanghai Fosun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	03-25
Shanghai Fosun Pharma Unit's Oral Schizophrenia Drug Gets Marketing Registration	03-14
Fosun Pharma Unit Gets China OK for Phase I Trial for Solid Tumor Drug	03-08
Fosun Pharma Unit to Start First Phase of Trial of Cancer Drug Candidate	03-07
Fosun Pharma Chairman Proposes Buyback of Up to 200 Million Yuan	03-04
Fosun Pharma Subsidiaries Get Nod to Trial Leukemia Drugs	02-29
Registration Application of Hypokalemia Drug by Shanghai Fosun Pharmaceutical Unit Accepted by Chinese Regulator	02-20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Hong Kong S.E.

Equities

2196

CNE100001M79

Other languages

Filters